United States Patent 8,623,406: Claim Scope, Validity, Orange Book Status, and Vascepa Patent Landscape
U.S. Patent No. 8,623,406 protects a dosing-and-treatment method for reducing triglycerides in patients receiving statin therapy. The claimed regimen uses 2.5 to 5 grams per day of ethyl eicosapentaenoate, or ethyl-EPA, with narrower claims covering approximately 1-gram capsules, at least 90% ethyl-EPA compositions, LDL-C reduction, and mixed dyslipidemia.
The patent is associated with Amarin’s Vascepa, whose active ingredient is icosapent ethyl. The patent’s nominal term runs to December 2029, subject to patent-term adjustment, terminal disclaimers, and any effect of judicial validity determinations. Its commercial strength is narrower than a broad composition patent because every independent method claim requires statin therapy, a specific daily dose, and triglyceride reduction.
What does U.S. Patent 8,623,406 protect?
The patent claims treatment of a patient on statin therapy with high-dose ethyl-EPA. Claim 1 is the broadest claim:
| Claim element |
Requirement |
| Patient |
A subject in need of triglyceride reduction |
| Background therapy |
The subject is on statin therapy |
| Active ingredient |
Ethyl eicosapentaenoate |
| Daily dose |
2,500 mg to 5,000 mg |
| Treatment result |
Reduction of triglycerides |
| Treatment duration |
A period effective to reduce triglycerides |
The claim is a method-of-use claim rather than a composition claim. It does not require a particular disease label, triglyceride threshold, capsule size, manufacturing process, or brand name.
The claim also does not expressly require that ethyl-EPA be the only omega-3 component. That limitation appears in dependent claim 8, which requires ethyl-EPA to comprise at least about 90% by weight of the fatty acids in the composition.
How do the individual claims differ?
Claims 1, 9, and 10: therapeutic-use limitations
Claim 1 requires the complete treatment regimen. Claim 9 adds LDL-C reduction, creating a dual-outcome limitation. A practicing product would need to reduce both triglycerides and LDL-C for literal infringement of claim 9.
Claim 10 requires that the subject have mixed dyslipidemia. The claim does not define mixed dyslipidemia by a specific LDL-C or triglyceride cutoff. Regulatory labeling, clinical protocols, and ordinary medical usage would likely inform how that term is interpreted.
Claims 2 through 7: dosage-unit limitations
Claims 2 through 7 narrow claim 1 by specifying the amount of ethyl-EPA in each dosage unit:
| Claim |
Dosage-unit limitation |
Dosage form |
| 2 |
About 500 mg to about 1.5 g |
Not required |
| 3 |
About 500 mg to about 1.5 g |
Capsules |
| 4 |
About 900 mg to about 1 g |
Not required |
| 5 |
About 900 mg to about 1 g |
Capsules |
| 6 |
About 1 g |
Not required |
| 7 |
About 1 g |
Capsules |
Claims 6 and 7 are particularly relevant to Vascepa because the marketed product uses 1-gram and 0.5-gram capsules, with the approved 4-gram daily regimen ordinarily administered as four 1-gram capsules or eight 0.5-gram capsules.
The word “about” creates a range that is broader than the stated numerical value. Its precise boundaries would depend on claim construction, specification context, prosecution history, and the relevant technical understanding of dosage-unit variation.
Claim 8: high-purity fatty-acid composition
Claim 8 requires a pharmaceutical composition containing other fatty acids or esters and at least about 90% ethyl-EPA by weight of the fatty acids present.
This limitation is important because it distinguishes the claimed product from conventional mixed omega-3 products containing substantial amounts of docosahexaenoic acid, or DHA. A competing product with pure or highly concentrated ethyl-EPA may fall within the claim if it is used in the claimed statin-treatment regimen.
What is the patent’s legal status and expiration date?
| Field |
Information |
| Patent |
U.S. Patent No. 8,623,406 |
| Title |
Methods of reducing triglycerides in a subject on statin therapy |
| Patent type |
Method-of-treatment patent |
| Patent holder associated with product |
Amarin-related entities |
| Issue date |
January 7, 2014 |
| Earliest priority basis |
December 2008 provisional filing chain |
| Nominal expiration |
December 2029 |
| Product association |
Vascepa, icosapent ethyl |
| Regulatory product |
FDA-approved prescription capsule |
| Orange Book relevance |
Method-of-use listing associated with Vascepa |
The patent term is generally calculated from the earliest effective nonprovisional filing date, not from the issue date. A December 2029 expiration date is consistent with the patent family’s December 2009 nonprovisional filing chronology and the standard 20-year term framework under 35 U.S.C. § 154.
An accurate freedom-to-operate analysis must check the current USPTO Patent Center record, terminal disclaimers, patent-term adjustment, and the current FDA Orange Book listing. An issued patent can remain listed while being subject to enforceability or validity challenges.
What patents protect Vascepa and icosapent ethyl?
Vascepa has been protected by a layered patent estate rather than by a single patent. The main categories are:
| Patent category |
Protection provided |
Commercial significance |
| High-purity ethyl-EPA compositions |
Concentrated icosapent ethyl compositions |
Product identity and purity |
| Hypertriglyceridemia treatment |
Use in patients with elevated triglycerides |
Original Vascepa indication |
| Statin-combination treatment |
Use in patients already receiving statins |
REDUCE-IT-related indication |
| Dosage regimens |
Daily dosing and capsule configurations |
Generic label and prescribing exposure |
| Cardiovascular-risk reduction |
Use in statin-treated patients with cardiovascular risk |
Later expanded indication |
| Manufacturing and formulation |
Purification, capsule, and production processes |
Potential supply-chain barriers |
U.S. Patent 8,623,406 sits primarily in the statin-combination and triglyceride-reduction category. It is narrower than a composition patent because infringement depends on how the product is prescribed, labeled, or used.
Other Vascepa-related patents publicly associated with the product include U.S. Patent Nos. 8,293,728, 8,357,677, 8,389,578, 8,648,048, 8,795,675, 9,700,435, and 10,568,861. Their precise scope and expiration dates differ. Some relate to high-purity EPA compositions, while later patents relate to cardiovascular-risk reduction and expanded treatment populations.
What is the Orange Book status of U.S. Patent 8,623,406?
The Orange Book identifies patents and regulatory exclusivities submitted for approved drug products. For Vascepa, the relevant listed patents have historically included composition and method-of-use patents covering icosapent ethyl and its approved indications.
A method-of-use patent does not automatically block every generic sale. The practical effect depends on:
- Whether the generic applicant files a Paragraph IV certification.
- Whether the generic label includes the patented indication.
- Whether the branded company sues within the statutory 45-day period.
- Whether the court grants an injunction or finds the patent valid and infringed.
- Whether a skinny label removes the patented use.
For a patent such as 8,623,406, the key regulatory question is whether a generic label directs use in statin-treated patients at the claimed dose for triglyceride reduction. A generic applicant may attempt to omit the patented indication while retaining an approval for a nonpatented use.
When does 8,623,406 lose exclusivity?
The nominal patent expiration is in December 2029. FDA drug exclusivity is separate from patent exclusivity.
Vascepa received FDA approval in 2012 for severe hypertriglyceridemia and expanded approval in 2019 for cardiovascular-risk reduction in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors.[2] The 2019 approval did not reset the patent term for earlier-issued patents.
The relevant exclusivity periods are:
| Exclusivity type |
General duration |
Vascepa relevance |
| New chemical entity exclusivity |
Five years |
Expired |
| Three-year clinical-investigation exclusivity |
Three years for qualifying change |
Expired |
| Patent exclusivity |
Patent-specific |
Certain patents run into 2029 or later |
| Orphan exclusivity |
Seven years |
Not the principal Vascepa framework |
| Pediatric exclusivity |
Six months if granted |
Must be verified separately |
Generic icosapent ethyl products entered the U.S. market before the expiration of every Vascepa-related patent because FDA approval and market entry depended on the outcome of ANDA litigation and the scope of the generic labels.
Which companies challenged Vascepa patents?
The most important challengers were Hikma Pharmaceuticals and Dr. Reddy’s Laboratories. Both pursued abbreviated new drug applications for generic icosapent ethyl and became involved in patent litigation with Amarin.
The litigation centered on Vascepa patents covering high-purity EPA, treatment regimens, and the cardiovascular-risk-reduction indication. In 2020, the U.S. District Court for the District of Nevada found asserted Vascepa patents invalid for obviousness in litigation involving Hikma and Dr. Reddy’s.[3] The decision materially weakened Amarin’s ability to exclude generic entry based on the asserted patents.
The publicly reported invalidity ruling focused principally on later Vascepa patents, including U.S. Patent Nos. 9,700,435 and 10,568,861. Patent 8,623,406 should be analyzed separately from those claims. The fact that a related Vascepa patent was invalidated does not, by itself, invalidate every patent in the family or every claim directed to a different treatment population.
How strong are the claims of U.S. Patent 8,623,406?
Infringement strength
The patent has meaningful infringement potential against a generic label that expressly instructs:
- Use with statins;
- A 4-gram daily dose;
- Treatment of elevated triglycerides;
- Use in mixed dyslipidemia; or
- Use of 1-gram capsules.
The strongest practical claims are likely claims 1, 6, and 7 when a generic product is labeled for a 4-gram daily regimen delivered through 1-gram capsules.
The claim is weaker against a generic product that uses a label limited to a nonstatin population or omits the cardiovascular-risk-reduction indication. However, induced-infringement exposure can arise from product labeling, promotional materials, dosing instructions, physician knowledge, and the ordinary use of the product.
Validity strength
Potential validity challenges include:
- Obviousness based on prior EPA studies;
- Obviousness of combining high-dose ethyl-EPA with statin therapy;
- Lack of predictable clinical benefit;
- Written-description challenges to the claimed population or result;
- Enablement challenges involving the full 2.5-to-5-gram dose range;
- Claim-construction disputes concerning “about,” “mixed dyslipidemia,” and “period effective to reduce.”
The most significant obviousness issue is whether prior art would have motivated a skilled person to use highly purified ethyl-EPA at the claimed dose in statin-treated patients with a reasonable expectation of triglyceride reduction. The clinical evidence supporting the method, including REDUCE-IT, may assist infringement and commercial positioning but does not automatically cure an obviousness defect if the claimed regimen was already suggested by the prior art.
What generic entry risks exist?
Generic entry risk depends on the product label and the remaining enforceable patents.
| Generic scenario |
Risk to branded product |
| Full label covering all Vascepa indications |
High patent-litigation exposure |
| Skinny label omitting cardiovascular-risk reduction |
Lower method-of-use exposure |
| 4-gram dose with 1-gram capsules |
Direct relevance to claims 1, 6, and 7 |
| Mixed omega-3 product |
Lower risk under claim 8, but other patents may apply |
| Highly purified ethyl-EPA product |
Higher composition and method-patent exposure |
| Off-label physician prescribing |
Potential induced-infringement issue |
| Authorized generic or settlement launch |
Commercial entry may occur before patent expiry |
The most likely post-litigation market structure is multiple generic icosapent ethyl products competing on price, with branded Vascepa relying on prescriber familiarity, payer access, supply, and the cardiovascular-risk-reduction evidence base.
Are biosimilars relevant to Vascepa?
No. Vascepa is a small-molecule drug containing icosapent ethyl, not a biologic. The relevant competitors are ANDA-approved generic products, not biosimilars under the Public Health Service Act.
The approval pathway is 505(j), and patent disputes arise through Paragraph IV certifications under the Hatch-Waxman Act. Manufacturing equivalence, dissolution, impurity profiles, capsule composition, and labeling are more relevant than biosimilarity.
What licensing deals and geographic rights affect the patent estate?
The U.S. commercial rights to Vascepa have been controlled by Amarin-related entities. Amarin also has operated through regional partnerships and licensing arrangements outside the United States, particularly in territories where other companies commercialize or develop icosapent ethyl products.
Those arrangements do not automatically transfer U.S. patent ownership. A transaction review should distinguish:
- Patent ownership;
- Exclusive license rights;
- Sublicense rights;
- Regulatory sponsorship;
- Territory restrictions;
- Manufacturing rights;
- Settlement rights with generic challengers.
The principal geographic strength of Patent 8,623,406 is U.S.-specific. Equivalent protection in Europe, Canada, Japan, and other jurisdictions depends on separate national patents, prosecution outcomes, supplementary protection certificates, and local validity law.
What manufacturing and formulation barriers remain?
Patent 8,623,406 itself does not claim a manufacturing process. It can be infringed by use of a qualifying product regardless of whether the product is manufactured by the same process as Vascepa.
Manufacturing barriers may nevertheless arise from:
- Achieving high ethyl-EPA purity;
- Controlling oxidation and peroxide formation;
- Maintaining capsule stability;
- Matching dissolution and bioavailability specifications;
- Removing DHA and other fatty-acid impurities;
- Scaling purification and encapsulation;
- Preserving supply-chain quality during storage.
These barriers are regulatory and technical rather than direct limitations of the ’406 patent.
What is the revenue exposure from this patent?
Vascepa generated a substantial portion of Amarin’s commercial value during the period before generic competition. U.S. net product revenue increased sharply after the 2019 cardiovascular-risk-reduction approval and reached approximately $614 million in 2020.[4]
Patent 8,623,406 contributed to protection of the statin-treated triglyceride population, but it was only one component of the broader estate. The revenue exposure from this patent alone cannot be separated from the value of composition patents, later cardiovascular-use patents, FDA labeling, and market exclusivity.
After generic entry, the primary risks were price erosion, formulary substitution, reduced branded volume, and loss of negotiating leverage with payers.
Key Takeaways
- U.S. Patent 8,623,406 claims a method of reducing triglycerides with 2.5 to 5 grams per day of ethyl-EPA in a patient receiving statin therapy.
- Claims 6 and 7 directly cover approximately 1-gram capsule dosage units.
- Claim 8 adds a composition requirement of at least approximately 90% ethyl-EPA among the fatty acids present.
- Claims 9 and 10 narrow the method to LDL-C reduction and mixed dyslipidemia, respectively.
- The nominal patent term runs through December 2029.
- The patent is a method-of-use patent and does not independently claim the manufacturing process for icosapent ethyl.
- Generic entry is governed by Hatch-Waxman Paragraph IV litigation, skinny-label strategy, and the enforceability of the broader Vascepa patent estate.
- Hikma and Dr. Reddy’s successfully challenged important Vascepa patents, materially weakening the branded exclusion strategy.
- Biosimilar law is not relevant because Vascepa is a small-molecule drug.
- The patent’s strongest commercial relevance is against a generic label directing statin-treated patients to use 4 grams per day for triglyceride reduction.
Frequently Asked Questions
Does Patent 8,623,406 cover all uses of icosapent ethyl?
No. It requires statin therapy, a 2.5-to-5-gram daily dose, and triglyceride reduction. Uses outside those limitations are not within claim 1.
Does a 4-gram Vascepa dose fall within Patent 8,623,406?
Yes. A 4-gram daily dose falls within the claimed 2.5-to-5-gram range. A regimen using four 1-gram capsules also implicates claims 6 and 7.
Can a generic manufacturer avoid the patent by omitting the cardiovascular indication?
Potentially, but omission does not eliminate all risk. A label directed to statin-treated patients for triglyceride reduction may still fall within claim 1.
Is mixed dyslipidemia required for infringement?
No. Mixed dyslipidemia is required only for claim 10. Claim 1 does not include that limitation.
Does the patent cover purified EPA made by a different process?
The patent does not require a particular manufacturing process. If the resulting product and use satisfy the claimed treatment limitations, a different manufacturing process would not necessarily avoid infringement.
References
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,623,406: Methods of reducing triglycerides in a subject on statin therapy.
- U.S. Food and Drug Administration. (2019). FDA approves use of Vascepa to reduce risk of cardiovascular events in adults with elevated triglyceride levels.
- Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 19-cv-00334, U.S. District Court for the District of Nevada (2020).
- Amarin Corporation plc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Vascepa prescribing information.
